TITLE

Rimonabant: An Answer to Overweight in Diabetes?

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
February 2007
SOURCE
Travel Medicine Advisor;Feb2007, Vol. 17 Issue 2, Special section p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on the impact of Rimonabant (RBT) on overweight diabetic subjects with reference to a study conducted by A. J. Scheen et al, published in a 2006 issue of "Lancet." According to the article, the use of RBT resulted to weight loss in non-diabetic overweight and obese subjects. Study results showed that RBT has greater weight loss than diet and exercise alone in type 2 diabetics.
ACCESSION #
24779422

 

Related Articles

  • The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient. Kozakowski, Jarosław; Lebovitz, Harold E.; Kiciak, Adam; Zgliczyński, Wojciech; Tarnowski, Wiesław // Videosurgery & Other Miniinvasive Techniques / Wideochirurgia i;Dec2014, Vol. 9 Issue 4, p627 

    Obesity and type 2 diabetes mellitus have reached epidemic proportions worldwide. As the majority of antidiabetic medications are of limited efficacy and patient adherence to long-term therapy is one of the main limiting factors of effective blood glucose and body weight control, new therapies...

  • Low-Carb Improvements. Karl, E. // Diabetes Health;Sep2005, Vol. 14 Issue 9, p32 

    Discusses research being done on the benefits of a low-carbohydrate diet to obese people with type 2 diabetes. Reference to a study published in the March 2005 issue of "Annals of Internal Medicine" journal; Details of the diet assigned to the patients involved in the study; Recorded weight...

  • Call for more gastric banding for type 2 diabetes.  // British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p377 

    The article reports on the call for greater consideration of gastric banding as an option for obese people with type 2 diabetes in Great Britain. It mentions that the gastric banding procedure is a highly effective option for selected obese patients who fail to reduce their weight through...

  • Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery. Zalesin, Kerstyn C.; Krause, Kevin R.; Chengelis, David L.; McCullough, Peter A. // Vascular Disease Prevention;May2008, Vol. 5 Issue 2, p75 

    Background: The association between body mass index (BMI) and the development of type 2 diabetes (T2DM) is well established. The determinants of the resolution of T2DM with weight reduction after bariatric surgery, however, are not fully understood. Objective: Examine the course of T2DM during...

  • Key Global Literature. Fonseca, Vivian // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2339 

    Provides information on a randomized study of orlistat in combination with a weight management program in obese patients with type 2 diabetes treated with metformin. Comparison between orlistat treatment and placebo; Impact of orlistaton glycemic control and the lipid profile in type 2 diabetes.

  • Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes. Redmon, J. Bruce; Reck, Kristell P.; Raatz, Susan K.; Swanson, Joyce E.; Kwong, Christine A.; Ji, Hong; Thomas, William; Bantle, John P. // Diabetes Care;Jun2005, Vol. 28 Issue 6, p1311 

    OBJECTIVE -- To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS -- A total of 59 overweight or obese individuals with type 2 diabetes...

  • Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis. Branis, Natalia M.; Wittlin, Steven D. // Case Reports in Endocrinology;4/19/2015, Vol. 2015, p1 

    Obesity is common in patients with type 1 and type 2 diabetes. Amphetamine-like analogues comprise the most popular class of weight loss medications. We present a case of a 34-year-old African American female with a history of type 1 diabetes, dyslipidemia, and obesity who developed diabetic...

  • Progressive Reduction in Body Weight with Pramlintide Therapy in Obese Subjects with Type 2 Diabetes Treated with Diet and Exercise and/or Metformin. Edelman, Steve; Lush, Cameron; Kesty, Nicole; Burns, Colleen; Weyer, Christian; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, has several clinical effects relevant to obesity, including meal-related satiation, reduced food intake, and weight loss. We previously reported that 16-wk PRAM treatment resulted in a placebo (PBO)-corrected change in body weight...

  • Retinol Binding Protein-4 Between in Lean, Obese and Type 2 Diabetic Subjects: Lack of Effect of Caloric Restriction and Rosiglitazone. Dandona, Paresh; Ghanim, Husam; Mohanty, Priya; Ling, Ching; Viswanathan, Prabhakar // Diabetes;Jun2007 Supplement 1, Vol. 56, pA469 

    Retinol Binding protein (RBP)-4 is an adipocyte secreted protein which has been proposed as a mediator/inducer of insulin resistance in mice. Recent human studies showing higher RBP-4 concentrations in the insulin resistant states of type 2 DM and obesity which falls following weight loss...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics